Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

MJFOX Letterman, Dopamine levels, cell death and biomarkers
AMBS OWNS ALL BIOMARKER PATENTS: And the discussion around what
causes lower dopamine levels is cell death.
Basically he was surely all over AMBS but legally could not say
company name. It was clear it was orientated to this company's
recent news.

From tonight, MJFOX said, "With a biomarker, a trigger, we can see how the disease progresses."
Also he said that the drop in Dopamine was caused from Cell Death.
Letterman Stressed this fact with Michael, it was a clear connection to Amarantus Bioscience.

As you know both topics are Key in Recent information released by Amarantus, the close proximity of these topics to the news release indicates that MJFOX was refering to this company, IN MY HUMBLE OPINION.

Thanks to aewilliamson on this board for starting this thread!






With the acquisition of these assets, Amarantus added following issued patents to its portfolio:

12/802,630 – Diagnosis of Parkinson's Disease
13/118,175 – Assays for diagnosis and therapeutics...ALS and Parkinson's Disease
12/069,807 – 47 Protein Biomarkers for Neurodegenerative Diseases
12/804,868 – Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders
13/153,669 – Diagnosis of Alzheimer's Disease
SOURCE: http://ih.advfn.com/p.php?pid=nmona&article=55596624


MJFOX ON DAVID LETTERMAN 1/10/12
WATCH YOUTUBE HERE:

MJFOX ON KATIE COURIC 12/28/12
http://www.katiecouric.com/tag/michael-j-fox/




MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-
Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing
apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine
approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially
focusing on the development of MANF-based protein therapeutics. MANF’s current lead indication is Parkinson’s disease with additional focus on Traumatic Brain Injury (TBI. Future
indications may include myocardial infarction and certain rare and ultra-rare orphan diseases
where MANF is currently being evaluated.


The Company also owns an inventory of 88 cell lines referred to as “PhenoGuard Cell Lines.”
MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line, and it is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System will be identified from the Company’s inventory of PhenoGuard Cell Lines.